- Entry
- $19.04
- Final
- $18.37 -3.5%
- Target
- —
- Score
- -0.35
TL;DR Fulgent ($FLGT) trades at ~$18.5 with net cash of ~$26.9 /share, yet its core diagnostics business still grows +7% YoY, market penetration <1%, and TAM set to expand ~7× this decade. Previous “cash-rich traps” either never hit liftoff (Vivus, Sesen) or were past their peak (BlackBerry, Sun). Fulgent is solidly in the steep-growth part of the S-curve. ⸻ What is Fulgent? • Core lab: CLIA-certified NGS diagnostics (oncology, reproductive, rare disease) • 2024 results: Core revenue $281.2 M (+7% …
— ORIGINAL POST ·
Mr. Market Round 2: Why the “Value Trap” Label on $FLGT Doesn’t Add Up Thesis
· r/investing
· Apr 28, 2025